Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. - Wikidata - awgldk - TriplyDB

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

http://www.wikidata.org/entity/Q33380559

about

Alterations in cell cycle and induction of apoptotic cell death in breast cancer cells treated with α-mangostin extracted from mangosteen pericarp A comprehensive overview of targeted therapy in metastatic renal cell carcinoma Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Targeting angiogenesis in gynecologic cancers Combination therapy for renal cell cancer: what are possible options?Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.A phase I study of sunitinib plus bevacizumab in advanced solid tumors.Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.A current review of targeted therapeutics for ovarian cancer.Antivascular therapy for epithelial ovarian cancer.Targeted therapy in ovarian cancer.Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.High drug-loading nanomedicines: progress, current status, and prospects.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials Investigational agents in development for the treatment of ovarian cancer Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee Proteomics and ovarian cancer: integrating proteomics information into clinical care Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab The drug cocktail network Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias The prospects of pazopanib in advanced renal cell carcinoma.Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.

P2860

Q21285004-C50826C8-D7A0-4A47-8173-9976721EB73C Q24606852-A4B80693-D301-4352-950E-38C43CC8AA70 Q26750649-D8A912B1-157D-4658-9AB8-2547C12C0C18 Q26751280-02438740-E7BD-4684-9AEE-D0BA1225C510 Q26774515-D026C7F9-C7D8-4994-892F-BD51B7875699 Q26824766-E8B84F91-8DEC-4C0D-8248-FE162ED6F558 Q27011663-4BD5E20F-EE2A-4AAE-926D-68AA02A7C6EA Q28304985-E5351AEB-B216-46BA-9BFB-0B5D34475A89 Q33162197-DDF2A50D-E404-4E60-B16A-7281261B1602 Q33386345-7489DED6-08F3-47C8-8756-BA17520ED18F Q33414769-FBE99AF9-88A1-4835-A06E-C3AFC930694E Q33415219-198F051A-26D1-4F9C-B0A9-8687760869F3 Q33430382-D608BDC8-0695-4624-B348-8D688B774363 Q33580998-BD91E1CE-6961-49D2-909F-5F0E3D2F4E1E Q33583598-FAA05C9B-E01E-48C9-988D-9946A32EC26E Q33622179-B3151647-2FF9-4D51-9593-F93CFB6DF525 Q33658626-9FDB3FD4-41F2-4E15-9E7E-C5E3B207C43E Q33727047-C3445FF7-38AD-4A7A-BDB4-AB034FE5D7FC Q33766568-02D265E8-31AC-43D4-831A-F412301D03DA Q33807542-FC7534BA-54AC-445B-826B-AA658FDC08DC Q33849805-28963384-74D0-4E8E-AF3F-71ED6A7FACB9 Q33920800-B4545C92-5C1D-41AC-A11E-AD4185414D95 Q34036032-92A4FCCC-3D21-4B04-AE7C-DD47AC170AFC Q34056295-0C9C75AD-24D3-498D-BF2D-B482018161D8 Q34126627-25B37D90-73E0-4D8A-86CE-F2AB8C87904B Q34127380-98422684-AE2F-4001-88CF-72EF797E315F Q34131801-82B5AE4E-1D28-4941-A57C-61FD0DA4C2A0 Q34147360-A84402D3-F32E-4A83-A4C6-4CC0B7F711FF Q34363435-58CF63B3-8852-4CE5-B871-2FF0A4030CAF Q34417804-B262786A-E286-4DB3-9EBC-17A41EE32C91 Q34436908-B98CADE4-F910-41F8-BB68-B071DC859A26 Q34517849-6BB278E9-09F4-46CA-B392-B5B91301C59F Q34627163-CF929416-EC4F-42AC-91A5-29C1172BA643 Q34629803-6EB9CB8E-2D61-40B0-9F0C-42A262631C9F Q34656393-AA2B635B-1465-4C52-96CD-73F08AE9EED8 Q34781970-93868763-5699-479D-B5C0-6EA86A370F56 Q34956830-F242216E-04AA-494F-B99B-6BAA4C13945F Q34972161-B4D3E49E-CAAA-43D2-A662-37291496C146 Q35050558-A3AF19F9-8C28-4CB5-AA05-C01B2BD6AA8B Q35069647-AB442E89-5531-43BF-848C-126755E677A2

P2860

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

http://www.wikidata.org/entity/Q33380559

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Combination targeted therapy w ...... xicity and antitumor activity.

@ast

Combination targeted therapy w ...... xicity and antitumor activity.

@en

type

label

Combination targeted therapy w ...... xicity and antitumor activity.

@ast

Combination targeted therapy w ...... xicity and antitumor activity.

@en

prefLabel

Combination targeted therapy w ...... xicity and antitumor activity.

@ast

Combination targeted therapy w ...... xicity and antitumor activity.

@en

P1433

Q33380559-ED5C63B5-114E-4F7F-8CA3-147ABE1866A0

P1476

Q33380559-6FAB7D5F-6DB0-4D2D-ADDC-40C26C51B97B

P2093

Q33380559-07D812B1-119B-4586-9F53-53AE8B476CEC

Q33380559-1C0AEFE8-8DDF-425B-B92B-DC0D5C56DB9A

Q33380559-2B6C23D7-7B3F-4503-924F-0D19D94E5CD0

Q33380559-5D2E68E6-898B-4465-A0B5-B7BAD8F88FF1

Q33380559-5F26415C-121C-4108-A8D6-C657867FB04A

Q33380559-68B0B620-7746-4396-A59B-F9251B216728

Q33380559-7A4831C4-AA3D-494F-A0DC-A060BE4F0732

Q33380559-9E615509-089A-47BF-9E3D-64BCC1AD37EF

Q33380559-A011EE50-2A99-482B-A514-72B3672A1500

Q33380559-A87B757D-E4E4-49C1-8F45-1FBD684E0AB9

P304

Q33380559-5E4EC942-DBA7-4108-8770-64D243DD3178

P31

Q33380559-9869C8F6-9FF6-4C43-B152-B6F965F883CA

P356

Q33380559-655C5F47-81E2-43A1-8D9F-3F629BA2151B

P407

Q33380559-516DABA5-93F1-4738-8C24-3BA96CA383AE

P433

Q33380559-6B61EE6C-5F5D-4206-9514-CE24EEC2C623

P478

Q33380559-2F58D2F2-F681-457B-8025-64F5D751E792

P577

Q33380559-21C99DEF-AD4D-48B2-8855-8A6AD762C4FD

P698

Q33380559-8DA9E2A7-D942-44C4-873F-79386E5BF577

P921

Q33380559-8767D156-0151-4226-ACE9-25AAE320FAF2

P356

JCO.2007.10.8332

P1433

Journal of Clinical Oncology

P1476

Combination targeted therapy w ...... xicity and antitumor activity.

@en

P2093

Ahalya Premkumar

http://www.w3.org/2001/XMLSchema#string

Catherine Chow

http://www.w3.org/2001/XMLSchema#string

Christina M Annunziata

http://www.w3.org/2001/XMLSchema#string

Deborah McNally

http://www.w3.org/2001/XMLSchema#string

Edwin M Posadas

http://www.w3.org/2001/XMLSchema#string

Elise C Kohn

http://www.w3.org/2001/XMLSchema#string

Gisele Sarosy

http://www.w3.org/2001/XMLSchema#string

Helen X Chen

http://www.w3.org/2001/XMLSchema#string

Herbert L Kotz

http://www.w3.org/2001/XMLSchema#string

John J Wright

http://www.w3.org/2001/XMLSchema#string

P304

3709-3714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.10.8332

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18669456

http://www.w3.org/2001/XMLSchema#string

P921